Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy

Rachael A. Powis, Evangelina Karyka, Penelope Boyd, Julian Come, Ross A. Jones, Yinan Zheng, Eva Szunyogova, Ewout J.N. Groen, Gillian Hunter, Derek Thomson, Thomas M. Wishart, Catherina G. Becker, Simon H. Parson, Cecile Martinat, Mimoun Azzouz, Thomas H. Gillingwater*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

66 Citations (Scopus)
171 Downloads (Pure)


The autosomal recessive neuromuscular disease spinal muscular atrophy (SMA) is caused by loss of survival motor neuron (SMN) protein. Molecular pathways that are disrupted downstream of SMN therefore represent potentially attractive therapeutic targets for SMA. Here, we demonstrate that therapeutic targeting of ubiquitin pathways disrupted as a consequence of SMN depletion, by increasing levels of one key ubiquitination enzyme (ubiquitin-like modifier activating enzyme 1 [UBA1]), represents a viable approach for treating SMA. Loss of UBA1 was a conserved response across mouse and zebrafish models of SMA as well as in patient induced pluripotent stem cell–derive motor neurons. Restoration of UBA1 was sufficient to rescue motor axon pathology and restore motor performance in SMA zebrafish. Adeno-associated virus serotype 9–UBA1 (AAV9-UBA1) gene therapy delivered systemic increases in UBA1 protein levels that were well tolerated over a prolonged period in healthy control mice. Systemic restoration of UBA1 in SMA mice ameliorated weight loss, increased survival and motor performance, and improved neuromuscular and organ pathology. AAV9-UBA1 therapy was also sufficient to reverse the widespread molecular perturbations in ubiquitin homeostasis that occur during SMA. We conclude that UBA1 represents a safe and effective therapeutic target for the treatment of both neuromuscular and systemic aspects of SMA.
Original languageEnglish
Article numbere87908
JournalJCI Insight
Issue number11
Publication statusPublished - 21 Jul 2016


  • muscular atrophy
  • neuromuscular disease
  • therapeutic targets


Dive into the research topics of 'Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy'. Together they form a unique fingerprint.

Cite this